Age-Related Macular Degeneration (AMD) - Beta Study Telemedicine Assessment

The purpose of this study is to evaluate the compliance of the Foresee Home device in intermediate AMD patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age-Related Macular Degeneration Eye Diseases Macular Degeneration Retinal Degeneration Retinal Diseases

Age range

50 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Vitreos retina center

Toms River, New Jersey, United States

About this study

This is a non-randomized cohort, multi-center study. The eligible subjects will be asked to use the FORESEE HOME device daily and the tests results will be automatically transmitted to the Data Monitor Center for analysis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects who successfully completed participation in ForeseeHome-US2 study
Patients with ability to comprehend and sign the informed consent/authorization

Exclusion criteria

Subjects who failed to complete participation in ForeseeHome-US2 study

Treatment and study plan

Foresee Home

Device

Home Monitoring

Primary outcomes

Subject compliance with Foresee HomeTM device

Time frame: 6 months

Secondary outcomes

Assessment of the Telemedicine infrastructure

Time frame: 6 months

Sponsors and collaborators

Lead sponsor

Notal Vision Ltd.

Industry

Registry information

Acronym: AMD

Important dates

Study start: 2009
Primary completion: 2010
Study completion: 2010
First posted: Mar 9, 2010
Registry last updated: Sep 23, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed